Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Either those blips cause a fall in CD4 cell counts

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154183
(Total Views: 473)
Posted On: 09/13/2019 8:29:15 AM
Posted By: ohm20
Re: trding #8036
Either those blips cause a fall in CD4 cell counts or a drop in the CD4 cell counts may be the cause. Most likely it's a circular path that feeds off each other. Either way a lower CD4 count can cause untold problems. The HIV drugs I took a quick look at seemed to have an increased CD4 count between 50-100 c/ml, leronlimab's is 200+ c/ml.
Quote:
The most surprising finding over recent years, however, has been reports that several clinical outcomes previously thought to be unrelated to HIV infection are more common in those with low CD4 cell counts. Data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A) Study suggest that the risk of mortality from several non-AIDS causes is increased at lower CD4 cell counts, including deaths from liver-related causes. In the SMART trial, patients randomized to interrupted treatment had a higher risk of major cardiovascular, renal, and hepatic disease than those
randomized to continued treatment, suggesting an impact of HIV on these events (although a possible impact of prior treatment followed by discontinuation cannot be ruled out). In the CPCRA FIRST study , each doubling in the latest CD4 cell count was associated with a 20% reduction in the risk of non-AIDS diseases, with similar associations noted between the latest CD4 cell count and renal, cardiovascular, and non-AIDS cancer events. The EuroSIDA study has reported that both pancreatitis and chronic renal failure were less common in those with higher CD4 cell counts.



(2)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us